When initiating Soliqua 100/33, patients typically begin with a dose of 15 units injected once daily as a subcutaneous infusion. The dose can be adjusted by 10 to 15 units every three days or more frequently, based on the individual's fasting plasma glucose levels. The maximum daily dose is 60 units [1].
What is Soliqua 100/33 used for?
Soliqua 100/33 is a combination medication used for adults with type 2 diabetes mellitus to improve glycemic control. It combines insulin glargine (a long-acting basal insulin) with lixisenatide (a GLP-1 receptor agonist) [1].
How is Soliqua 100/33 administered?
Soliqua 100/33 is administered as a once-daily subcutaneous injection. It should be injected into the abdominal area, thigh, or upper arm. Patients should not inject it into a vein or muscle [1].
What is the recommended starting dose for Soliqua 100/33?
The recommended starting dose for Soliqua 100/33 is 15 units injected subcutaneously once daily. This dose can be titrated based on fasting plasma glucose [1].
How should Soliqua 100/33 dosage be adjusted?
Dose adjustments for Soliqua 100/33 should be made based on the patient's fasting plasma glucose. Increases can be made in increments of 10 to 15 units every three days or more frequently, as needed to reach target fasting plasma glucose levels. The maximum daily dose is 60 units [1].
What are the risks associated with Soliqua 100/33?
The risks associated with Soliqua 100/33 include hypoglycemia (low blood sugar), gastrointestinal adverse reactions, and pancreatitis. It is also associated with a boxed warning regarding the risk of thyroid C-cell tumors observed in animal studies, although it is unknown if Soliqua causes these tumors in humans [1].
When does Soliqua 100/33 patent protection end?
Information regarding the specific patent expiry dates for Soliqua 100/33 is available through resources like DrugPatentWatch.com [2]. Generally, patents for combination drugs and their formulations can have varying expiration dates.
What are the alternatives to Soliqua 100/33?
Alternative treatments for type 2 diabetes include other basal insulins, GLP-1 receptor agonists, metformin, and other classes of oral or injectable antidiabetic medications. The choice of alternative depends on individual patient needs, glycemic control goals, and tolerability [3].
What are the clinical trials for Soliqua 100/33?
Clinical trials for Soliqua 100/33 have evaluated its efficacy and safety in improving glycemic control in adults with type 2 diabetes. Studies like LIXILAN-O and LIXILAN-II demonstrated its effectiveness compared to other treatment regimens [4].
What are common side effects of Soliqua 100/33?
Common side effects of Soliqua 100/33 include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite. Hypoglycemia is also a significant potential side effect [1].
Sources:
[1] https://www.soliqua100-33.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.niddk.nih.gov/health-information/diabetes/overview-diabetes/type-2-diabetes
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780506/